Pharmacological Actions of Cannabinoids
The DOI matches its Crossref record; 218 of the 218 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ahluwalia, J., Yaqoob, M., Urban, L., Bevan, S., & Nagy, I. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01550.x · Cited by 83
RetractedInternational Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Self-citationStructure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Ledent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Imperato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,614
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Self-citationInternational Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Self-citationVanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H.-H., Sørgård, M., Di Marzo, V., Julius, D., & Högestätt, E. D. (1999) · Nature · doi:10.1038/22761 · Cited by 2,142
Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1
Jordt, S.-E., Bautista, D. M., Chuang, H.-H., McKemy, D. D., Zygmunt, P. M., Högestätt, E. D., Meng, I. D., & Julius, D. (2004) · Nature · doi:10.1038/nature02282 · Cited by 1,899
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“Surprisingly, SR141716 and the CB2 antagonist SR144528 were also reported to have antiinflammatory effects (Smith et al., 2000, 2001), which may be attributed to their inverse agonist properties or to CB1/2 receptor-independent mechanisms (reviewed in Begg et al., 2005; Pertwee, 2005b,c).”
BackgroundPertwee, R. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 1,935
Self-citationPertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., et al. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003004 · Cited by 1,605
Self-citationCannabinoid pharmacology: the first 66 years
Pertwee, R. G. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706406 · Cited by 782
Self-citationNeurobiological Interactions Between Stress and the Endocannabinoid System
Morena, M., Patel, S., Bains, J. S., & Hill, M. N. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.166 · Cited by 660
Endocannabinoid signaling as a synaptic circuit breaker in neurological disease
Katona, I., & Freund, T. F. (2008) · Nature Medicine · doi:10.1038/nm.f.1869 · Cited by 579
The pharmacology of cannabinoid receptors and their ligands: an overview
Pertwee, R. G. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803272 · Cited by 557
Self-citationHill, K. P. (2015) · JAMA · doi:10.1001/jama.2015.6199 · Cited by 508
Hermanns‐Clausen, M., Kneisel, S., Szabo, B., & Auwärter, V. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04078.x · Cited by 479
The Endocannabinoid System and Pain
Guindon, J., & Hohmann, A. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824660 · Cited by 476
Molecular Targets of the Phytocannabinoids: A Complex Picture
Morales, P., Hurst, D. P., & Reggio, P. H. (2017) · Progress in the Chemistry of Organic Natural Products · doi:10.1007/978-3-319-45541-9_4 · Cited by 454
Cannabidiol, neuroprotection and neuropsychiatric disorders
Campos, A. C., Fogaça, M. V., Sonego, A. B., & Guimarães, F. S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.033 · Cited by 446
Emerging strategies for exploiting cannabinoid receptor agonists as medicines
Pertwee, R. G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00048.x · Cited by 436
“…dependence, impaired fertility in some women, stroke, hypotension resulting from endotoxaemic shock triggered by advanced liver cirrhosis and intestinal hypomotility in paralytic ileus (Izzo and Coutts, 2005; Le Foll and Goldberg, 2005; Pertwee, 2005a; Di Marzo, 2008; Pertwee and Thomas, 2009).”
BackgroundInfluentialSelf-citationCrucian, B. E., Choukèr, A., Simpson, R. J., Mehta, S., Marshall, G., Smith, S. M., Zwart, S. R., Heer, M., Ponomarev, S., Whitmire, A., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01437 · Cited by 421
Is lipid signaling through cannabinoid 2 receptors part of a protective system?
Pacher, P., & Mechoulam, R. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2011.01.001 · Cited by 414
Mahler, S. V., Smith, K. S., & Berridge, K. C. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301376 · Cited by 377
Di Marzo, V. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.02.010 · Cited by 368
Endocannabinoids and the control of energy balance
Matias, I., & Di Marzo, V. (2007) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.11.006 · Cited by 365
Cannabinoid CB2 receptor: a new target for controlling neural cell survival?
Fernández-Ruiz, J., Romero, J., Velasco, G., Tolón, R. M., Ramos, J. A., & Guzmán, M. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.11.001 · Cited by 362
SUGIURA, T., KISHIMOTO, S., OKA, S., & GOKOH, M. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.03.003 · Cited by 352
Receptors and Channels Targeted by Synthetic Cannabinoid Receptor Agonists and Antagonists
Pertwee, R. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790980050 · Cited by 335
Self-citationEndocannabinoids and Their Pharmacological Actions
Pertwee, R. G. (2015) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-319-20825-1_1 · Cited by 300
Self-citationCB1 Cannabinoid Receptors and their Associated Proteins
Howlett, A., Blume, L., & Dalton, G. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790980023 · Cited by 295
Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models
Jayamanne, A., Greenwood, R., Mitchell, V. A., Aslan, S., Piomelli, D., & Vaughan, C. W. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706510 · Cited by 287
Resstel, L. B. M., Tavares, R. F., Lisboa, S. F. S., Joca, S. R. L., Corrêa, F. M. A., & Guimarães, F. S. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00046.x · Cited by 283
“It has a low affinity for cannabinoid receptors (Petitet et al., 1998; Thomas et al., 1998) although, under certain circumstances, it may act as an antagonist of CB1and CB2-receptor agonists (Pertwee et al., 2002).”
BackgroundThe endocannabinoid system in obesity and type 2 diabetes
Di Marzo, V. (2008) · Diabetologia · doi:10.1007/s00125-008-1048-2 · Cited by 281
Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals
Legare, C. A., Raup-Konsavage, W. M., & Vrana, K. E. (2022) · Pharmacology · doi:10.1159/000521683 · Cited by 275
Staton, P. C., Hatcher, J. P., Walker, D. J., Morrison, A. D., Shapland, E. M., Hughes, J. P., Chong, E., Mander, P. K., Green, P. J., Billinton, A., et al. (2008) · Pain · doi:10.1016/j.pain.2008.04.006 · Cited by 270
“In addition, given that CB2 has a role in regulating immune function through cytokine release [31], these studies were extended to include cytokine profiling experiments to investigate whether GPR55 signalling is also involved in the regulation of immune function.”
BackgroundBíró, T., Tóth, B. I., Haskó, G., Paus, R., & Pacher, P. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.05.004 · Cited by 271
McPartland, J. M., Glass, M., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707399 · Cited by 266
Self-citationThe direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA A receptors
Bakas, T., van Nieuwenhuijzen, P. S., Devenish, S. O., McGregor, I. S., Arnold, J. C., & Chebib, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.022 · Cited by 246
“However, whether the actions of 2-AG on GABAA receptors are relevant to these actions remains unclear given the large difference in potency (approximately 1000 fold) between 2-AG actions on CB1 receptors and those on GABAA receptors [68, 87].”
BackgroundEndocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.
Pacher, P., & Haskó, G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707582 · Cited by 217
Campos, A. C., & Guimarães, F. S. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.08.017 · Cited by 172
Cannabinoid facilitation of fear extinction memory recall in humans
Rabinak, C. A., Angstadt, M., Sripada, C. S., Abelson, J. L., Liberzon, I., Milad, M. R., & Phan, K. L. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.063 · Cited by 163
Clarke, J. R., Rossato, J. I., Monteiro, S., Bevilaqua, L. R. M., Izquierdo, I., & Cammarota, M. (2008) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2008.04.009 · Cited by 97
Actions of N-arachidonyl-glycine in a rat neuropathic pain model
Vuong, L. A. Q., Mitchell, V. A., & Vaughan, C. W. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.05.004 · Cited by 89
Ramikie, T. S., & Patel, S. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.037 · Cited by 62
Distinct Binding Mechanisms for Allosteric Sodium Ion in Cannabinoid Receptors
Dutta, S., Selvam, B., & Shukla, D. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00760 · Cited by 31
HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid
Haj, C. G., Sumariwalla, P. F., Hanuš, L., Kogan, N. M., Yektin, Z., Mechoulam, R., Feldmann, M., & Gallily, R. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.226100 · Cited by 26
Metadata
- Authors
- Pertwee, R. G.
- Venue
- Handbook of Experimental Pharmacology
- Publisher
- Springer-Verlag
- Published
- 2005-12-23
- Issue
- 168
- Pages
- 1-51
- OpenAlex
- W2131899215
- Cited by
- 597
- References
- 218
- FWCI
- 52.09
- Type
- book chapter
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.